Unknown

Dataset Information

0

Sequential response-driven bortezomib-based therapy followed by autologous stem cell transplant in AL amyloidosis.


ABSTRACT: Autologous stem cell transplant (ASCT) is highly effective in selected patients with light chain (AL) amyloidosis. Bortezomib, preceding or following ASCT, improves responses. Satisfactory responses, including at least a partial response, very good partial response (VGPR) with organ response, or complete response, can be observed after induction therapy alone. We report 139 patients treated upfront with cyclophosphamide/bortezomib/dexamethasone (CyBorD), followed by ASCT only if response was unsatisfactory. Only 1 treatment-related death was observed. After CyBorD, hematologic response (HR) rate was 68% (VGPR or better, 51%), with 45% satisfactory responses. Transplant was performed in 55 (40%) subjects and resulted in an 80% HR rate (65% ? VGPR). Five-year survival was 86% and 84% in patients treated with ASCT or CyBorD alone, respectively (P = .438). Also, 6- and 12- month landmark analyses did not show differences in survival. Duration of response was not different in the 2 groups (60 vs 49 months; P = .670). Twenty-one (15%) patients with an unsatisfactory response to CyBorD could not undergo ASCT because of ineligibility or refusal; instead, they received rescue chemotherapy, with HR in 38% of cases and 51% 5-year survival. This sequential response-driven approach, offering ASCT to patients who do not attain satisfactory response to upfront CyBorD, is very safe and effective in AL amyloidosis.

SUBMITTER: Basset M 

PROVIDER: S-EPMC7479942 | biostudies-literature | 2020 Sep

REPOSITORIES: biostudies-literature

altmetric image

Publications

Sequential response-driven bortezomib-based therapy followed by autologous stem cell transplant in AL amyloidosis.

Basset Marco M   Milani Paolo P   Nuvolone Mario M   Benigna Francesca F   Rodigari Lara L   Foli Andrea A   Merlini Giampaolo G   Palladini Giovanni G  

Blood advances 20200901 17


Autologous stem cell transplant (ASCT) is highly effective in selected patients with light chain (AL) amyloidosis. Bortezomib, preceding or following ASCT, improves responses. Satisfactory responses, including at least a partial response, very good partial response (VGPR) with organ response, or complete response, can be observed after induction therapy alone. We report 139 patients treated upfront with cyclophosphamide/bortezomib/dexamethasone (CyBorD), followed by ASCT only if response was uns  ...[more]

Similar Datasets

| S-EPMC3895846 | biostudies-literature
| S-EPMC8721454 | biostudies-literature
| S-EPMC6224498 | biostudies-literature
| S-EPMC7377298 | biostudies-literature
| S-EPMC6888142 | biostudies-literature
| S-EPMC6821610 | biostudies-literature
| S-EPMC2964067 | biostudies-literature
| S-EPMC8217489 | biostudies-literature
| S-EPMC5510147 | biostudies-other
| S-EPMC4342354 | biostudies-literature